Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Merck
Express Scripts
Boehringer Ingelheim
McKinsey

Last Updated: January 18, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Alisertib

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Alisertib?

Alisertib is an investigational drug.

There have been 47 clinical trials for Alisertib. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2012.

The most common disease conditions in clinical trials are Lymphoma, Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI), and Takeda.

There are seventeen US patents protecting this investigational drug and two hundred and thirteen international patents.

Recent Clinical Trials for Alisertib
TitleSponsorPhase
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung CancerTakedaPhase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung CancerCollin BlakelyPhase 1
Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCLColumbia UniversityPhase 3

See all Alisertib clinical trials

Clinical Trial Summary for Alisertib

Top disease conditions for Alisertib
Top clinical trial sponsors for Alisertib

See all Alisertib clinical trials

US Patents for Alisertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Alisertib   Start Trial Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-D][2]benzazepin-2-YL]amino}-2-methoxybenzoate Millennium Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
Alisertib   Start Trial Combinations of LSD1 inhibitors for use in the treatment of solid tumors Oryzon Genomics, S.A. (Madrid, ES)   Start Trial
Alisertib   Start Trial Combination of aurora kinase inhibitors and anti-CD30 antibodies Millennium Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
Alisertib   Start Trial Combination of aurora kinase inhibitors and anti-CD20 antibodies Millennium Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Alisertib

Drugname Country Document Number Estimated Expiration Related US Patent
Alisertib Brazil 112012020557 2030-02-19   Start Trial
Alisertib Canada 2788774 2030-02-19   Start Trial
Alisertib China 102770024 2030-02-19   Start Trial
Alisertib China 104031049 2030-02-19   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
McKinsey
Harvard Business School
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.